Bistratal Au@Bi2S3 nanobones for excellent NIR-triggered/multimodal imaging-guided synergistic therapy for liver cancer

Bioactive Materials

Penghui Cao¹  Hui Wang²  Tianyu Zong²  Chenyu Dai²  Yuhao Li²  Pengpeng Jia²  Yuqing Miao²  Jie Yuan²  Shuang Zhou²  Dong Sun²  Ruizhuo Ouyang²  Ning Guo³ 

[1] Corresponding authors.;Institute of Bismuth Science, University of Shanghai for Science and Technology, Shanghai, 200093, China;School of Chemistry and Chemical Engineering, Henan Normal University, Xinxiang, 453007, China;

关键词: Au@Bi2S3 NBs;    DOX;    CT;    Photothermal conversion;    Cancer treatment;   

DOI  :  

来源: DOAJ

【 摘 要 】

To fabricate a highly biocompatible nanoplatform enabling synergistic therapy and real-time imaging, novel Au@Bi2S3 core shell nanobones (NBs) (Au@Bi2S3 NBs) with Au nanorods as cores were synthesized. The combination of Au nanorods with Bi2S3 film made the Au@Bi2S3 NBs exhibit ultrahigh photothermal (PT) conversion efficiency, remarkable photoacoustic (PA) imaging and high computed tomography (CT) performance; these Au@Bi2S3 NBs thus are a promising nanotheranostic agent for PT/PA/CT imaging. Subsequently, poly(N-vinylpyrrolidone)-modified Au@Bi2S3 NBs (Au@Bi2S3-PVP NBs) were successfully loaded with the anticancer drug doxorubicin (DOX), and a satisfactory pH sensitive release profile was achieved, thus revealing the great potential of Au@Bi2S3-PVP NBs in chemotherapy as a drug carrier to deliver DOX into cancer cells. Both in vitro and in vivo investigations demonstrated that the Au@Bi2S3-PVP NBs possessed multiple desired features for cancer therapy, including extremely low toxicity, good biocompatibility, high drug loading ability, precise tumor targeting and effective accumulation. Highly efficient ablation of the human liver cancer cell HepG2 was achieved through Au@Bi2S3-PVP NB-mediated photothermal therapy (PTT). As both a contrast enhancement probe and therapeutic agent, Au@Bi2S3-PVP NBs provided outstanding NIR-triggered multi-modal PT/PA/CT imaging-guided PTT and effectively inhibited the growth of HepG2 liver cancer cells via synergistic chemo/PT therapy.

【 授权许可】

Unknown